Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25 ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

This collection of health news showcases a range of significant developments: measles cases are surging in Texas and New ...

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...

The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.